Ellie Leick

In light of the COVID-19 pandemic, transplant-eligible patients with cancer are undergoing careful assessment to determine whether they should proceed with the procedure or receive additional consolidation therapy to buy time, according to Naval G. Daver, MD.

Although the emergence of more targeted and immunotherapies continues to expand the melanoma treatment paradigm, surgery remains an important tool in the management of these patients, according to Omid Hamid, MD.

Retrospective results showed that African-American women with endometrial cancer are less likely to receive evidence-based care compared with white women.

Biomarker-driven treatments continue to expand in prostate cancer, as research efforts explore responses across different subgroups, explained Petros Grivas MD, PhD.

Autologous stem cell transplantation continues to have a significant role for patients with high-risk myeloma; however, research efforts continue to focus on novel induction, consolidation, and maintenance regimens, as well as the use of tandem transplant, explained Andrew Branagan, MD.

The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.

Updated data on several emerging treatment modalities were presented at the 2019 ASH Annual Meeting in multiple myeloma, including CAR T-cell therapy, antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and a novel selinexor (Xpovio) combination, explained Sandy W. Wong, MD.

Research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) had a significant effect on the standard of care for patients with HER2-positive metastatic breast cancer, explained Erika P. Hamilton, MD.

The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.

The approval of several TKIs and combination regimens has led to more treatment options for patients with renal cell carcinoma (RCC), with a heavier focus on individualized approaches, explained Ajjai Shivaram Alva, MBBS.

Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for potential molecular drivers of their disease, explained Nathan Pennell, MD, PhD.

After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination, according to Melissa L. Larson, MD.

JAK inhibitors have been the standard of care for patients with myelofibrosis, but now patients need novel agents to help.

New approvals in the treatment of patients with myeloma has led to the question of what sequencing of drugs will work best for patients.

Biosimilars are beginning to change the way oncology professionals treat patients with cancer, and this could help alleviate the financial burden of care.

Multiple CDK4/6 inhibitors have shown impressive OS survival benefit in multiples studies of patients with metastatic HR+ breast cancer.

With the help of NGS, new research is emerging for targeted therapies of rare mutations in lung cancer.

Steps in orthopedic oncology are being made after the first-ever global perspective trial in its field completed patient accrual.

Several late-stage therapies, including targeted agents and immunotherapies, are being evaluated for patients with relapsed/refractory colorectal cancer (CRC) who have progressed on first- and second-line therapies.

Switch maintenance treatment with pembrolizumab (Keytruda) improved progression-free survival (PFS) in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy, according to results of a randomized phase II study that were presented at the 2019 ASCO Annual Meeting.

A recent survey found that oncology professionals are most concerned about the cost of cancer care drugs, obtaining reimbursement for other services, transparency in commercial policies and direct patient care rather than paperwork.

A recent study looked at the role that patients' stress and anxiety plays in deciding on treatment for patients with prostate cancer.

A recent study aimed to determine the when and why chemotherapy-induced cognitive impairment, or chemobrain, occurs, who is most likely to develop it, and whether certain factors (such as age, race, menopausal status, etc) play any role.

In some cases, patients with cancer who are rejected from clinical trials because they are "too sick," are the patients who would benefit the most from the trial.

A blood test that tracks patients’ antibody levels could predict when oropharyngeal cancer is likely to recur during its earliest.

Longer intervals between zoledronic acid doses for patients with bone metastases did not result in an increased risk of skeletal-related events (SREs).

A recent study explored the link between the genetic mutations and cisplatin-induced hearing loss.

While urinary incontinence and erectile dysfunction are two burdensome side effects from prostate cancer treatment, new online programs are showing promise in helping men cope in both the short and long term.

Patients with cancer who have Medicaid coverage or who are uninsured are more likely to be diagnosed later and receive improper treatment for cancer, according to two recent studies, and these factors can have an impact on their survival.

A study involving women with a BRCA mutation who had risk-reducing surgery to lower their risk of breast and/or ovarian cancer found that many of these individuals have surgical procedures such as oophorectomy or mastectomy without a full understanding of how they will affect their sexuality and other aspects of their lives.